New drug shows promise for rare fat disorder in small trial
NCT ID NCT04159415
First seen Nov 17, 2025 · Last updated May 12, 2026 · Updated 20 times
Summary
This study tested a new drug called REGN4461 in 16 people with generalized lipodystrophy, a rare condition where the body lacks fat tissue, leading to severe metabolic problems like high blood sugar and high triglycerides. The drug aims to mimic a natural hormone (leptin) to improve these levels. Results focused on changes in blood sugar and fat levels after 8 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Research Site
Bethesda, Maryland, 20892, United States
-
Regeneron Research Site
Ann Arbor, Michigan, 48105, United States
-
Regeneron Research Site
Dallas, Texas, 75390, United States
-
Regeneron Research Site
Piura, 2665, Peru
-
Regeneron Research Site
Moscow, 117036, Russia
-
Regeneron Research Site
Ankara, 06230, Turkey (Türkiye)
-
Regeneron Research Site
Diyarbakır, 21808, Turkey (Türkiye)
-
Regeneron Research Site
Izmir, 35100, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.